Okskarbazepina – miejsce w leczeniu padaczki Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2021
Słowa kluczowe:
okskarbazepina, napady ogniskowe, skuteczność, bezpieczeństwo, interakcje lekowe, zaburzenia seksualne, zaburzenia depresyjne
##plugins.themes.bootstrap3.article.main##
Abstrakt
Okskarbazepina jest zalecana jako lek pierwszego rzutu w monoterapii oraz terapii dodanej zarówno u dzieci, jak i dorosłych z napadami ogniskowymi. Jest dość dobrze tolerowana i rzadziej wchodzi w interakcje z innymi lekami, a ewentualne działania niepożądane rzadziej prowadzą do zaprzestania terapii. Istotną cechą leku jest pozytywny wpływ na sferę seksualną chorych oraz przypuszczalny pozytywny wpływ na zmniejszenie objawów depresyjnych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kopka, M. (2021). Okskarbazepina – miejsce w leczeniu padaczki . Medycyna Faktów , 14(1(50), 98-101. https://doi.org/10.24292/01.MF.0121.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Schachter SC, Vazquez B, Fisher RS et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999; 52: 732-7.
2. Sachdeo R, Beydoun A, Schachter S et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001; 57(5): 864-71.
3. Rov T, Biswas A. Oxcarbamazepine, the new effective anti-epileptic drug for add-on as well as monotherapy in partial epilepsies. J Indian Med Assoc. 2002; 100(5): 336.
4. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009; (4). Art No. CD006453.
5. Nevitt SJ, Marson AG, Weston J et al. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2018, Issue 10. Art. No. CD003615.
6. Kanner AM, Ashman E, Gloss D et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018; 91(2): 74‐81.
7. Jędrzejczak J, Majkowska-Zwolińska B, Ryglewicz D et al. Zalecenia Polskiego Towarzystwa Epileptologii dotyczące leczenia napadów padaczkowych u dorosłych. Aktualizacja. J Epileptol. 2019; 27: 5-12.
8. NICE: 2004, 2018.
9. Abou-Khalil BW. Update on Antiepileptic Drugs 2019. Continuum (Minneap Minn). 2019; 25(2): 508-36.
10. Berghuis B, van der Palen J, de Haan GJ et al. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia. 2017; 58(7): 1227‐33.
11. Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opinion on Drug Safety 2016. http://doi.org/10.1080/14740338.2017.1248399.
12. Mazurkiewicz-Bełdzińska M, Czuczwar S. Leki przeciwpadaczkowe. In: Białecka M, Sławek J. Interakcje leków w neurologii. Via Medica, Gdańsk 2015: 161-98.
13. Veroniki AA, Cogo E, Rios P et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017; 15: 95.
14. Campbell E, Kennedy F, Russell A et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014; 85: 1029-34.
15. Hernandez-Diaz S, Smith CR, Shen A et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012; 78: 1692-9.
16. Tomson T, Battino D, Bonizoni E et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018; 17(6): 530‐8.
17. Baker GA, Bronley RL, Briggs M et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015; 84(4): 382-90.
18. US Food and Drug Administration. FDA drug safety communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. June 5, 2013 (accessed Sept 12, 2017).
19. European Medicines Agency. Assessment report: procedure under article 31 of directive 2001/83/EC resulting from pharmacovigilance data. Oct 9, 2014 (accessed April 10, 2015).
20. Herzog AG. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure. 2008; 17: 101-10.
21. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res. 2000; 12: 305-11.
22. Herzog AG. Reproductive endocrine regulation in men with epilepsy: effects on reproductive function and neuronal excitability. Ann Neurol. 2002; 51: 539-42.
23. Mattson RH, Cramer JA. Epilepsy, sex hormones, and antiepileptic drugs. Epilepsia. 1985; 26(suppl. 1): 40-51S.
24. Luef G, Krämer G, Stefan H. Oxcarbazepine treatment in male epilepsy patients improves pre-existing sexual dysfunction. Acta Neurol Scand. 2009; 119(2): 94‐9.
25. Tellez-Zenteno JF, Patten S, Williams J et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007; 48(12): 2336‐44.
26. Jobe PC. Common pathogenetic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy Behav. 2003; 4: S14-24.
27. Jones JE, Hermann BP, Woodard JL et al. Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia. 2005; 46: 731-5.
28. Mazza M, Della Marca G, Di Nicola M et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav. 2007; 10397-401.
2. Sachdeo R, Beydoun A, Schachter S et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001; 57(5): 864-71.
3. Rov T, Biswas A. Oxcarbamazepine, the new effective anti-epileptic drug for add-on as well as monotherapy in partial epilepsies. J Indian Med Assoc. 2002; 100(5): 336.
4. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009; (4). Art No. CD006453.
5. Nevitt SJ, Marson AG, Weston J et al. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2018, Issue 10. Art. No. CD003615.
6. Kanner AM, Ashman E, Gloss D et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018; 91(2): 74‐81.
7. Jędrzejczak J, Majkowska-Zwolińska B, Ryglewicz D et al. Zalecenia Polskiego Towarzystwa Epileptologii dotyczące leczenia napadów padaczkowych u dorosłych. Aktualizacja. J Epileptol. 2019; 27: 5-12.
8. NICE: 2004, 2018.
9. Abou-Khalil BW. Update on Antiepileptic Drugs 2019. Continuum (Minneap Minn). 2019; 25(2): 508-36.
10. Berghuis B, van der Palen J, de Haan GJ et al. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia. 2017; 58(7): 1227‐33.
11. Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opinion on Drug Safety 2016. http://doi.org/10.1080/14740338.2017.1248399.
12. Mazurkiewicz-Bełdzińska M, Czuczwar S. Leki przeciwpadaczkowe. In: Białecka M, Sławek J. Interakcje leków w neurologii. Via Medica, Gdańsk 2015: 161-98.
13. Veroniki AA, Cogo E, Rios P et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017; 15: 95.
14. Campbell E, Kennedy F, Russell A et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014; 85: 1029-34.
15. Hernandez-Diaz S, Smith CR, Shen A et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012; 78: 1692-9.
16. Tomson T, Battino D, Bonizoni E et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018; 17(6): 530‐8.
17. Baker GA, Bronley RL, Briggs M et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015; 84(4): 382-90.
18. US Food and Drug Administration. FDA drug safety communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. June 5, 2013 (accessed Sept 12, 2017).
19. European Medicines Agency. Assessment report: procedure under article 31 of directive 2001/83/EC resulting from pharmacovigilance data. Oct 9, 2014 (accessed April 10, 2015).
20. Herzog AG. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure. 2008; 17: 101-10.
21. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res. 2000; 12: 305-11.
22. Herzog AG. Reproductive endocrine regulation in men with epilepsy: effects on reproductive function and neuronal excitability. Ann Neurol. 2002; 51: 539-42.
23. Mattson RH, Cramer JA. Epilepsy, sex hormones, and antiepileptic drugs. Epilepsia. 1985; 26(suppl. 1): 40-51S.
24. Luef G, Krämer G, Stefan H. Oxcarbazepine treatment in male epilepsy patients improves pre-existing sexual dysfunction. Acta Neurol Scand. 2009; 119(2): 94‐9.
25. Tellez-Zenteno JF, Patten S, Williams J et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007; 48(12): 2336‐44.
26. Jobe PC. Common pathogenetic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy Behav. 2003; 4: S14-24.
27. Jones JE, Hermann BP, Woodard JL et al. Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia. 2005; 46: 731-5.
28. Mazza M, Della Marca G, Di Nicola M et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav. 2007; 10397-401.